Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Ashley Cordova, the Chief Executive Officer of NovoCure Ltd (NASDAQ:NVCR), recently sold a significant portion of the company’s ordinary shares, according to a recent SEC filing. The transactions, which took place on February 27 and 28, 2025, involved the sale of a total of 13,494 shares. The shares were sold at prices ranging from $18.2843 to $20.549, amounting to a total transaction value of $266,126. The timing is notable as the stock has declined over 10% in the past week, with current trading near $18.41, significantly below its 52-week high of $34.13.
Post-transaction, Cordova holds 206,058 shares directly. These sales were executed in multiple trades, with varying prices per share, and reflect Cordova’s ongoing adjustments to her holdings in the company. Investors often closely monitor such transactions by company executives to gauge insider sentiment.
In other recent news, Novocure reported its fourth-quarter earnings, which did not meet analyst expectations, although the company surpassed revenue estimates. The earnings showed a loss of $0.61 per share, missing the analyst projection of a $0.36 loss by $0.25. Despite this, Novocure’s revenue for the quarter was $161.26 million, exceeding the consensus estimate of $153.04 million and representing a 21% year-over-year increase. For the full year 2024, the company’s net revenues reached $605.2 million, marking a 19% increase from the previous year. This growth was primarily driven by the launch of Optune Gio for glioblastoma in France and improved approval rates in the U.S.
Novocure also announced the FDA approval of Optune Lua for treating metastatic non-small cell lung cancer, with its commercial rollout underway in the U.S. Additionally, the company’s Phase 3 PANOVA-3 trial achieved its primary endpoint, showing significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer. As of the end of 2024, Novocure reported 4,126 active patients on its Tumor Treating Fields therapy worldwide. The company ended the year with $959.9 million in cash, cash equivalents, and short-term investments. Looking forward, Novocure anticipates modest growth in its glioblastoma business in 2025 and expects gross margins to be influenced by ongoing product enhancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.